UPPSALA, Sweden, 20 October 2021 / PRNewswire / – Biotage AB (Released) (“Biotage“) today entered into an agreement to acquire all of the outstanding shares of the private company ATDBio Limited (“ATDBio“) situated at Oxford and Southampton, United Kingdom, for a total purchase price of approx. 45 MGBP on a debt-free and cash-free basis (corresponding to approximately MSEK 534.4) financed by the combination of an issue of new Biotage ordinary shares, available cash and a revolving credit facility. The transaction was closed as part of the conclusion of the share purchase contract.
The acquisition of ATDBio adds important platform solutions to Biotage for the synthesis and purification of DNA and RNA oligonucleotides. This technology is used for applications in drug discovery, molecular diagnostics (such as PCR testing), nucleic acid-based therapies, and next-generation DNA and RNA sequencing technologies. The acquisition of the UK company is expected to significantly expand and strengthen Biotage as a leading life sciences tool and provider of impact technology services. ATDBio was founded by professor Tom Brown father, recognized expert in nucleic acid chemistry, in 2004.
ATDBio’s expertise in the production of highly complex DNA and RNA will provide Biotage with market access and know-how in the rapidly growing sector of DNA and RNA oligonucleotides. This market is currently driven by the demand for high quality DNA and RNA molecules and other oligonucleotide analogues in light of the coronavirus pandemic, as well as the potential for other therapies, vaccines and diagnostics. molecules based on nucleic acid.
“We are very happy to welcome ATDBio to the Biotage Group family. Our companies are very complementary and share the same vision to shape the science of tomorrow and the discoveries of tomorrow. Step by step, Biotage is expanding its chemical modalities platforms and portfolio offering. From peptide purification and higher volume small molecule research, we have already expanded to purification of lipids for use in mRNA vaccines as well as purification of plasmid DNA, including viral purification for gene therapy. We are now entering the attractive new oligonucleotide market“, comments Tomas blomquist, CEO and President of Biotage.
“ATDBio is very proud to be part of the Biotage family, which shares our passion for innovation, customer focus and sustainability. With our in-depth understanding of nucleic acid chemistry, we can ensure high quality oligonucleotide synthesis and deliver high purity products. We manufacture oligonucleotides for a wide variety of academic and commercial customers, including some of the world’s largest biotech and pharmaceutical companies. We will now be able to grow even further thanks to Biotage’s global presence and cutting-edge expertise in separation science. We will continue to innovate, helping our customers bring the next generation of molecular nucleic acid diagnostics, vaccines and therapeutics to market.“said Dr Tom brown jr, director of ATDBio.
The combination of ATDBio’s specialized and large-scale expertise in DNA and RNA oligonucleotide production and innovation with Biotage’s one-stop workflow and customer platform solutions has great potential. With Biotage having recently gained market share in the large-scale flash purification of lipids used for the formulation of lipid nanoparticles of mRNA vaccines, there is already a successful approach that can be applied for other DNA chemical modalities and of RNA in different drug and therapeutic discoveries. applications. Chemically synthesized RNA is also required for CRISPR / Cas gene editing technology, the discovery and development of which led to the award of the 2020 Nobel Prize in Chemistry.
ATDBio generated a net turnover of 3.5 MGBP in 2020, corresponding to approx. 41.6 MSEK and an operating result (EBIT) of 1.0 MGBP, corresponding to approx. SEK 11.9 million. To be compared with the first nine months of 2021 for a net turnover of 4.5 MGBP. ATDBio had 20 full-time employees at September 30, 2021.
All ATDBio shares are acquired from ATDBio shareholders through a share purchase agreement with Biotage for consideration in shares and cash. The total purchase price of all ATDBio shares is approx. 45 MGBP, corresponding to approx. 534.4 MSEK, on a debt-free and cash-free basis, and includes approx. 16 MGBP (around 190 MSEK) into 781,991 newly issued ordinary shares in Biotage and approx. 29 MGBP (approximately 344.4) MSEK in cash. Of which 5 MGBP (corresponding to approximately 59.4 MSEK) of the total purchase price consists of a future payment of the expected additional purchase price which, in the end, must be paid after three years.
The transaction will be financed by a share issue of 781,991 new Biotage common shares combined with available cash and a revolving credit facility. The issue of shares against contribution in kind was decided today by the Board of Directors of Biotage pursuant to an authorization given by the General Meeting of April 28, 2021. Ordinary shares will be issued to ATDBio shareholders.
This is information that Biotage AB (publ) is required to make public in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the contact person indicated above, at 8:30 a.m. CEST on 20 October 2021.
Tomas blomquist, CEO
Phone: 0705 23 01 63, [email protected]
Biotage is a Global Impact Tech Company committed to solving the problems of society. We provide workflow solutions and products to customers in the areas of drug discovery and development, analytical testing, and water and environmental testing. Biotage contributes to sustainable science with the goal of making the world healthier, greener and cleaner – HumanKind Unlimited.
Our clients cover a wide range of market segments including pharmaceutical, biotechnology, contract and contract research manufacturers, as well as clinical, forensic and academic laboratories, as well as organizations focused on food safety, drinking water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs approx. 485 people in the world. The Group achieved sales of MSEK 1,092 in 2020 and our products are sold in more than 70 countries. Biotage (BIOT) shares are listed on the Mid Cap segment of NASDAQ Stockholm.
 Based on a SEK / GBP exchange rate of 11.8765, used throughout this press release for the GBP / SEK conversion.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/biotage/r/biotage-acquires-atdbio-and-strengthens-its-position-in-dna-and-rna-oligonucleotide- synthese-and-pu, c3436384
The following files are available for download: